We are live on
!
Find out more
MWNA
Marshall Wace North America Portfolio holdings
AUM
$23.5B
1-Year Est. Return
46.46%
This Fund
S&P 500
This Quarter
Est. Return
+7.23%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$17.7B
AUM Growth
-$2.27B
(-11%)
Cap. Flow
-$3.05B
Cap. Flow
% of AUM
-17.25%
Top 10 Holdings %
Top 10 Hldgs %
15.77%
Holding
1,947
New
557
Increased
335
Reduced
444
Closed
606
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$113M |
| 2 |
BERY
Berry Global Group, Inc.
BERY
|
+$106M |
| 3 |
Merck
MRK
|
+$95.9M |
| 4 |
Baidu
BIDU
|
+$85.8M |
| 5 |
IQVIA
IQV
|
+$83.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$229M |
| 2 |
Las Vegas Sands
LVS
|
+$150M |
| 3 |
Alibaba
BABA
|
+$131M |
| 4 |
Citigroup
C
|
+$130M |
| 5 |
Micron Technology
MU
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.85% |
| 2 | Technology | 15.39% |
| 3 | Consumer Discretionary | 13.45% |
| 4 | Industrials | 10.48% |
| 5 | Financials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Akebia Therapeutics
AKBA
$252M
| $5.79M | 0.03% |
580,549
-17,738
| -3% | -$178K |
|
|
CTLT
477
DELISTED
CATALENT, INC.
CTLT
| $5.78M | 0.03% |
+138,018
| New | +$5.58M |
|
|
DLPH
478
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
| $5.77M | 0.03% |
126,984
+27,450
| +28% | +$1.37M |
|
479
First Horizon
FHN
$12.1B
| $5.74M | 0.03% |
+321,755
| New | +$6.05M |
|
|
XLRN
480
DELISTED
Acceleron Pharma
XLRN
| $5.71M | 0.03% |
+117,693
| New | +$4.29M |
|
|
XIFR
481
XPLR Infrastructure LP
XIFR
$1.08B
| $5.67M | 0.03% |
121,477
-100,646
| -45% | -$4.3M |
|
|
SNV
482
DELISTED
Synovus
SNV
| $5.64M | 0.03% |
106,797
+697
| +0.7% | +$37.1K |
|
483
Bio-Techne
TECH
$11.3B
| $5.63M | 0.03% |
+152,140
| New | +$5.81M |
|
|
USX
484
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $5.59M | 0.03% |
+368,923
| New | +$5.55M |
|
485
Salesforce
CRM
$158B
| $5.57M | 0.03% |
+40,804
| New | +$5.21M |
|
486
Rockwell Automation
ROK
$49B
| $5.56M | 0.03% |
+33,432
| New | +$5.81M |
|
|
JWN
487
DELISTED
Nordstrom
JWN
| $5.55M | 0.03% |
107,287
+32,993
| +44% | +$1.64M |
|
|
FISV
488
Fiserv Inc
FISV
$27.9B
| $5.54M | 0.03% |
74,750
-96,201
| -56% | -$6.99M |
|
|
RDS.B
489
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $5.51M | 0.03% |
+75,839
| New | +$5.46M |
|
490
LeMaitre Vascular
LMAT
$1.86B
| $5.49M | 0.03% |
164,027
+64,714
| +65% | +$2.3M |
|
|
TWO
491
Two Harbors Investment
TWO
$1.27B
| $5.49M | 0.03% |
86,844
+61,313
| +240% | +$3.84M |
|
492
Domino's
DPZ
$11.6B
| $5.47M | 0.03% |
19,391
-261,135
| -93% | -$66.2M |
|
|
CSII
493
DELISTED
Cardiovascular Systems, Inc.
CSII
| $5.45M | 0.03% |
168,619
-156,098
| -48% | -$4.3M |
|
494
Oracle
ORCL
$423B
| $5.42M | 0.03% |
+123,025
| New | +$5.67M |
|
|
ULTI
495
DELISTED
Ultimate Software Group Inc
ULTI
| $5.42M | 0.03% |
+21,051
| New | +$5.4M |
|
|
PDM
496
Piedmont Realty Trust
PDM
$1.19B
| $5.4M | 0.03% |
+270,861
| New | +$5.02M |
|
|
BDN
497
Brandywine Realty Trust
BDN
$554M
| $5.38M | 0.03% |
318,736
+239,270
| +301% | +$3.84M |
|
|
ACC
498
DELISTED
American Campus Communities, Inc.
ACC
| $5.22M | 0.03% |
+121,695
| New | +$4.87M |
|
|
RDS.A
499
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $5.21M | 0.03% |
+75,214
| New | +$5.21M |
|
500
National Beverage
FIZZ
$3.01B
| $5.16M | 0.03% |
96,466
+7,684
| +9% | +$361K |
|
Similar funds
TGHSA
PAM
HB
MWA
3SCA
HFCIV
DVC
NAM
Marshall Wace North America's Q2 2018 Portfolio in Review
As of Q2 2018, Marshall Wace North America held 1,947 positions worth $17.7B, down 11% from $20B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Marshall Wace North America withdrew a net $3.05B in Q2 2018, closing 606 positions and reducing 444 holdings. Its most notable exit was Time Warner Inc, an estimated $63.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Marshall Wace North America opened a new position in IQVIA worth $83.1M.
- Marshall Wace North America's largest Q2 2018 buy was IQVIA: 832,159 shares worth $83.1M.
- Marshall Wace North America added most to Vertex Pharmaceuticals in Q2 2018, an estimated $113M increase.
- Marshall Wace North America's biggest Q2 2018 reduction was Johnson & Johnson, cutting an estimated $229M.
- Marshall Wace North America fully exited Time Warner Inc in Q2 2018, selling an estimated $63.3M.
- Marshall Wace North America's ten largest holdings make up 16% of its $17.7B portfolio in Q2 2018.
- Marshall Wace North America opened 557 new positions and closed 606 in Q2 2018.
- Marshall Wace North America's portfolio value fell 11% quarter-over-quarter to $17.7B.
Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.